Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for immuno-inflammatory diseases. Headquartered in Wayne, Pennsylvania, the company operates primarily through its therapeutics segment, which focuses on addressing unmet medical needs in dermatology and immunology. Its clinical pipeline features both small molecules and biologics, including ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, and ATI-2138, an oral ITK/JAK3 inhibitor for conditions like lichen planus. Aclaris leverages its proprietary kinase small molecule discovery platform to advance its portfolio of next-generation signaling pathway inhibitors. The company also previously operated a contract research segment through its subsidiary Confluence Discovery Technologies, providing drug discovery services to the broader pharmaceutical industry.
